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Abstract: Synaptosomes are used to decipher the mechanisms involved in chemical transmission,
since they permit highlighting the mechanisms of transmitter release and confirming whether the
activation of presynaptic receptors/enzymes can modulate this event. In the last two decades,
important progress in the field came from the observations that synaptosomes retain changes elicited
by both “in vivo” and “in vitro” acute chemical stimulation. The novelty of these studies is the finding
that these adaptations persist beyond the washout of the triggering drug, emerging subsequently as
functional modifications of synaptosomal performances, including release efficiency. These findings
support the conclusion that synaptosomes are plastic entities that respond dynamically to ambient
stimulation, but also that they “learn and memorize” the functional adaptation triggered by acute
exposure to chemical agents. This work aims at reviewing the results so far available concerning
this form of synaptosomal learning, also highlighting the role of these acute chemical adaptations in
pathological conditions.
Keywords: synaptosomes; in vitro treatment; in vivo treatment; presynaptic receptors; functional
adaptation; transmitter release
1. Introduction
Along brain slices and cultured neurons, isolated nerve endings (we refer to as synaptosomes)
can help to elucidate the cascade of events involved in chemical transmission. Synaptosomes permit
studying the mechanism of transmitter exocytosis and dissecting the mechanism of control of this
functional parameter, allowing to prove the existence of presynaptic receptors, the activation of which
modulates the efficiency of transmitters overflow in the synaptic cleft.
Historically, two main approaches have been used to demonstrate the existence and the role of
presynaptic release-regulating receptors in isolated nerve terminals.
The first one relied on “in vitro” studies carried out to quantify the potency and the efficacy of
selected ligands at presynaptic release-regulating receptors controlling the transmitter overflows from
synaptosomes isolated from distinct regions of the central nervous system (CNS). The results from these
“in vitro” experiments also allowed predicting the composition in subunits of the receptor(s) under
study as well as identifying the enzymatic repertoire transducing the receptor-mediated signaling from
the outer to the inner side of the synaptosomal membranes [1–5].
The second one consisted of “ex vivo, in vitro” studies from synaptosomes that were isolated from
central regions of animals chronically administered with selective agonists/antagonists. In this case,
the working hypothesis relied on the assumption that, although synaptosomes are largely conserved
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structures, they develop persistent adaptations when the nerve endings they originate from are
chronically exposed to chemicals in intact tissue (i.e., as is supposed to occur in “in vivo” studies). These
structural/functional adaptations were proposed to rely on the onset of cascade of events (i.e., up- and
downregulation of receptor proteins, rearrangement of subunits assembly due to in–out constitutive
trafficking [5], phosphorylation of intraterminal proteins, genetic and epigenetic adaptations in protein
synthesis) strictly dependent on the nature of the receptors targeted and of the drug administered that
became detectable in “ex vivo, in vitro” as changes in the synaptosomal receptor repertoire and/or
release efficiency [6–8]. Because of the causative correlation linking the chronic drug administration and
the adaptive modifications, the results from “ex vivo, in vitro” studies were also considered largely
confirmatory of the presence and of the functional role of release-regulating presynaptic receptors in
selected subpopulations of nerve endings. In the meantime, however, they provided the first functional
evidence of the onset of a presynaptic form of “long term memory” in nerve terminals that could be
relevant to the mechanisms of synaptic plasticity and that should be taken into consideration when
analyzing the impacts of therapeutics on chemical transmission [9,10].
Important progress in the use of isolated nerve endings came from the observations that, in addition
to the abovementioned “in-vivo, long term memory”, synaptosomes also retain functional changes when
acutely exposed “in vitro” to receptor ligands/enzyme modulators. Very interestingly, and in a way
unexpectedly, it was demonstrated that the acute exposure of synaptosomes to chemicals primes these
particles, leading to functional modifications that persist beyond the washout of the triggering agent and
that emerge subsequently as changes in release efficiency. On the whole, these observations seemed
predictive of the onset of a form of acute “in vitro” synaptosomal memory [11]. Starting from this first
observation, data accumulated during the last decade were well consistent with this hypothesis. These
works also unveiled the onset of persistent adaptations in synaptosomes following the acute “in vivo”
administration of ligands targeting selected receptors/transporters. Again, the synaptic adaptations were
retained by the “ex vivo, in vitro” synaptosomes and were detectable in “in vitro” studies.
The present review aims at reviewing these observations, proposing the hypothesis that
synaptosomes can “learn and memorize” acute stimulations and could be useful to study the acute
plastic modifications of the presynaptic component of synaptic connection in the CNS.
2. Synaptosomes to Study Transmitter Release
At chemical synapsis, the release of neurotransmitters is fundamental to dictate the strength
and efficiency of the synaptic contacts. In general, the release of neurotransmitters is triggered
by action potentials that invade nerve terminals, permitting the influx of positive charges through
the Na+ and Ca2+ channels in plasmamembranes and the consequent activation of intraterminal
Ca2+-dependent pathways leading to exocytosis [12–15]. In addition to the massive activation of
nerve plasmamembranes, also local depolarization caused by the in–out movements of ions elicited
by ionotropic receptors (i.e., the AMPA and the NMDA receptors [16–18]) as well as by electrogenic
membrane transporters [19,20], can drive transmitter exocytosis. Notably, metabotropic receptors also
participate in defining the efficiency of transmitter exocytosis, but, differently from the ionotropic
receptors, they preferentially modulate intraterminal enzymatic pathways, finely tuning, rather than
eliciting, transmitter exocytosis [21–23].
In the CNS, the organization of the synaptic structures makes it very difficult to dissect the
presynaptic component of the chemical transmission from the postsynaptic one, especially in “in vivo”
studies or in “in vitro” studies carried out with tissue preparations with a higher level of complexity,
such as slices or cultured cells. This complexity, however, is significantly reduced when using
synaptosomes [24], a simplified tissue preparation that permits deciphering the presynaptic events [13].
During the last 70 years, studies with synaptosomes allowed describing:
(i) the mechanisms of storage and of release of transmitters in selected CNS regions [25–27];
(ii) the existence and the functional role of presynaptic release-regulating receptors [10,28];
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(iii) the functional and molecular adaptations of the presynaptic releasing machinery and of the
presynaptic receptors elicited by “in vivo” chronic drug administration [8,9,12];
(iv) the functional and molecular presynaptic changes elicited by genetic manipulation in animals [29,30].
3. Synaptosomes . . .
Synaptosomes are pinched-of nerve terminals isolated from synaptic boutons and from varicosities
of axonal processes. First described by Gray and Wittaker in 1962 [24], these particles represent a
simplified model to study the mechanism of uptake, storage, and release of classic transmitters and the
presynaptic processes that regulate these events. Synaptosomes retain the functional features of the
structures they originate from, permitting to describe their main characteristics. They possess native
enzymes, transporters and receptor proteins, maintaining the complexity of the organization of the
presynaptic component of chemical synapsis.
The transporters located in synaptosomal plasmamembranes take up the transmitter from the
external biophase and store it in the vesicular pool, from which the transmitter is subsequently released
upon the application of a depolarizing stimuli to the isolated nerve endings [31]. The specificity of the
expression of the carrier in the synaptosomal plasmamembranes assures the selective labeling of defined
subpopulations of nerve endings, respecting the geometry of the neuronal network. This selective
labeling makes it possible to distinguish among selected subpopulations of nerve terminals, despite the
heterogeneous composition of the synaptosomal suspension [32,33] and, as synaptosomes possess the
intraterminal machinery that permits the release of transmitter in an exocytotic manner [34], to associate
the stimulus-evoked release of a specific transmitter to the corresponding synaptosomal subpopulations,
regardless of the percentage of that synaptosomal subfamily with respect to the entire population. It is
worth stressing that the composition of the synaptosomal suspension can vary even if preparation
originates from the same CNS regions. Variability is an unavoidable experimental limitation that
depends on several parameters (including the animals, the multistep technical approach, and the ability
to manage the processes) that affect the efficiency of the isolation and purification of the synaptosomal
fractions (i.e., the number of synaptosomal particles isolated in each preparation). Another aspect that
might influence the results from synaptosomes is the contamination of the synaptosomal suspension
due to the presence of a certain percentage (about 3% to 5%) of particles that originate from astrocytes
(we refer to them as gliosomes [23]). The low percentage of this contamination together with the
selective labeling of the isolated nerve endings, however, minimizes the signaling due to the glial
fractions in both the functional studies and the biochemical analysis of the synaptosomal proteins.
It is worth reminding that in some cases, synaptosomes retain fragments of the postsynaptic
membranes. The impact of this component in release studies is, however, irrelevant, since the possibility
that in superfusion, endogenous substances originating from the postsynaptic side can retrogradely
affect the release efficiency at the presynaptic side is minimized by the continuums flowing up–down of
the medium that quickly removes any endogenous compounds, preventing their retrograde diffusion
from the postsynaptic to the presynaptic side of the synaptic contact (see below).
Finally, synaptosomes possess presynaptic receptors, whose activation controls most of the
synaptosomal activities, including transmitter release. Activation of presynaptic receptors tunes
the distribution of the ionic charges at the two sides of the membranes, as well as the functions
of intraterminal enzymatic pathways controlling phosphorylative processes and second messenger
productions. On the whole, these events promote or impede the formation of the SNARE complex and,
as a direct consequence, control the vesicular transmitter exocytosis.
4. . . . And Their Up–Down Superfusion to Monitor Transmitter Release
As to the quantitation of transmitter release, in 1974, Raiteri and colleagues [35] described
an experimental approach called the “the up-down superfusion of a thin layer of synaptosomes”
(reviewed by [13]), which has become the method of choice for the identification and the functional
characterization of defined subfamilies of nerve endings.
Int. J. Mol. Sci. 2019, 20, 3641 4 of 16
The main feature of this experimental approach is the continuous up–down superfusion with a
physiological solution of a monolayer of synaptosomes stratified at the bottom of superfusion chambers.
The up–down flowing of the superfusion medium assures the rapid removal of any substances at the
outer side of synaptosomes, impeding their re-uptake in the superfused particles. The endogenous
molecules released are rapidly removed and cannot interact with receptors located on bystander
particles. Furthermore, as already anticipated, the continuum superfusion also prevents retrograde
signaling from postsynaptic membranes to the presynaptic ones.
This experimental approach allows distinguishing between drugs that modulate directly the
release of transmitter (i.e., agonists acting at presynaptic release-regulating receptors) and drugs that
indirectly influence it, by interfering with the mechanism of the uptake (i.e., catecholamine uptake
inhibitors which indirectly augment the amount of catecholamine and indolamine availability in the
synaptic cleft) and that cannot modulate transmitter overflow in superfusion studies.
Using this approach, it was possible to describe and to pharmacologically and functionally
characterize several receptors presynaptically located on nerve endings, improving our knowledge of
the molecular events on the basis of the efficacy of a large part of therapeutics [23,34,36–39].
5. Presynaptic Release-Regulating Receptors
The finding that nerve terminals possess presynaptic receptors controlling the transmitter exocytosis
introduced a new concept in the synaptic transmission. Once considered exclusively unidirectional
(from the presynaptic to the postsynaptic component of the chemical synapses), this notion introduced
the concept that the chemical information at chemical synapsis can also proceed retrogradely, from the
synaptic cleft to the presynaptic component, modifying the efficiency of the chemical transmission [7].
The role of presynaptic release-regulating receptors in controlling the strength of the synaptic
connection made it imperative to classify them pharmacologically and functionally. In this context,
the superfusion of purified synaptosomes is one of the most appropriate models to correctly address the
question, since it permits a direct correlation between the occupation of the receptor and the functional
output. The results from these studies unveiled that the presynaptic release-regulating receptors are a
heterogeneous ensemble, consisting of entities that, based on their location and their functions, can be
further subclassified in “autoreceptors” and “heteroreceptors” [10].
Presynaptic autoreceptors are those receptors that are activated by the transmitter that is under the
control of the receptors themselves. They mediate a mechanism of feedback regulation of the release
of their natural activator, by preferentially inhibiting it. Differently, heteroreceptors are sensitive to
transmitter that are mainly released by adjacent nerve terminals and that are other than the neuron’s
own transmitter. Both auto- and heteroreceptors exert their feedback mechanisms of control of
transmitter release when exocytosis is elicited by a low to intermediate frequency of stimulation,
reflecting their physiological relevance in controlling chemical transmission.
The pharmacological and functional characterization of presynaptic release-regulating auto- and
heteroreceptors was preferentially accomplished in “in vitro” studies with synaptosomes in superfusion
by quantifying the potency and the efficacy of selective receptor ligands (either orthosteric and allosteric
agonists and antagonists [23,34,40–43]) as well as antibodies recognizing the outer sequences of the
receptor subunit proteins [39,44] that act as modulators of the receptor-mediated control of transmitter
release [45].
The efficiency in either activating or reducing the receptor-mediated events permits comparative
analysis of the pharmacological profiles of ligands but also confirms the existence of the presynaptic
release-regulating receptor in the synaptosomal preparation. The ability of selected ligands to modulate
transmitter exocytosis could also suggest the participation of a selected subunit to the assembly of
the receptor under study, allowing to predict the receptor subunit composition [39,44]. In general,
however, these conclusions require further studies to be confirmed, using nonfunctional approaches
including immunological experiments aimed at demonstrating the presence of the subunit proteins
in the synaptosomal subpopulation under study [46–49]. As to this possibility, it is worth stressing
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that subfractioning techniques are available that allow separating the presynaptic component of
synaptosomes from the postsynaptic ones [5,20], permitting to quantify the amount of receptor proteins
at the two sides of the synaptic contacts.
6. In Vivo Chronic Drug Administration and “Ex Vivo, In Vitro” Persistent Synaptosomal
Adaptations
Often, the “in vitro” studies aimed at the characterization of presynaptic receptors were paralleled
by “ex-vivo, in vitro” analysis carried out with synaptosomes isolated from CNS regions of animals
chronically administered with orthosteric/allosteric receptor ligands as well as carrier blockers, to tune
“in vivo” the activity of the presynaptic receptors. In addition to confirming the existence of the
presynaptic receptors, these studies also aimed at unveiling drug-induced functional and structural
adaptations at the presynaptic component of the synapsis. The results from these experiments
suggested that the chronic administration of receptor ligands/carrier modulators elicit structural and
functional remodeling of the synaptic proteasome. Interestingly, these adaptations emerged in “ex
vivo, in vitro” studies as a functional adaptation of the presynaptic receptor repertoire, as suggested by
the changes in the potency and the efficiency of the ligands acting at these proteins in synaptosomes
isolated from selected CNS regions of the treated animals. It is therefore not surprising that this
approach was also applied to confirm the involvement of a selected subpopulation of presynaptic
terminals in the synaptic network [6–9,34,50–52].
As far as the presynaptic receptors are concerned, the results from the “ex vivo, in vitro” studies
unveiled that, independently on how the receptor ligand controls transmitter exocytosis, auto- and
heteroreceptors respond differently to the chronic administration of selective agonists. Autoreceptors
preferentially downregulate when activated chronically by agonists and upregulate following chronic
deprivation of the endogenous transmitter. Differently, most of the heteroreceptors are refractory
towards the drug-evoked adaptation, and, in most cases, they did not undergo up- or down-sensitization
after long-lasting exposure to selective receptor ligands [6,34].
The molecular events accounting for the “in vivo” drug-induced functional modifications were
so far poorly investigated and deserve further studies. Nonetheless, whatever the mechanisms
involved, the drug-induced adaptations elicited by the “in-vivo” chronic administration of receptor
ligands provide the first demonstration that nerve terminals can undergo a form of presynaptic “long
term memory” that emerges subsequently in “ex vivo, in vitro” studies as functional changes in the
synaptosomal receptor repertoire and/or release efficiency.
Interestingly, in most of these studies, the impact of the acute drug administration on the same
functional parameters was rarely, if ever, analyzed, based on the assumption that only the continuous
“in vivo” drug delivery could assure the onset of persistent adaptations in nerve endings.
7. “In Vitro” Persistent “Presynaptic Adaptation” in Synaptosomes
Important progress in the knowledge of the dynamic adaptability of isolated nerve endings
emerged in 2003, when Bailey and colleagues provided the first evidence of the induction of a
chemical form of long-term depression (cLTD) in isolated presynaptic terminals [11]. The study
was an extension of a previous investigation showing that the elevation of the intracellular cyclic
guanosine monophosphate (cGMP, due to the blockade of the type V phosphodiesterase, PED5)
concomitant to the inhibition of the protein kinase type A (PKA), elicited a form of chemical LTD
(cLTD) at Schaffer collateral-CA1 and at mossy fiber-CA3 synapses. The cLTD was unaffected by
preventing postsynaptically the synaptic transmission; furthermore, the administration of both the
enzymes modulators at the postsynaptic level did not trigger a comparable signaling. Based on
these observations, the authors proposed that the cLTD in hippocampal slices was preferentially
a presynaptic event [53]. Accordingly, in 2003, the authors demonstrated that the exposure of rat
hippocampal synaptosomes in superfusion to the mixture of the enzyme inhibitors caused a prolonged
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inhibition of glutamate release efficiency from these particles, which appeared well consistent with the
LTD detected in slices (Table 1).
The novelty of this study was the timing of the experiments applied. The drug-induced
presynaptic adaptation in superfused synaptosomes was detected despite the triggering conditioning
drugs being removed far in advance. In particular, synaptosomes were superfused with a Kreb’s
ringer containing the two enzyme inhibitors, then replaced (again for 20 min) with drug-free
medium and finally challenged with a mild depolarizing stimulus (25 mM KCl for 30 s) to elicit
glutamate exocytosis. Despite the removal of the triggering agents and the washout period of 20 min,
the depolarization-evoked release of glutamate from treated synaptosomes was significantly reduced
when compared to untreated particles.
The authors concluded that the “in vitro” exposure of synaptosomes to both the enzyme
modulators caused a persistent adaptation in the isolated nerve endings, which persisted over time and
emerged as reduced transmitter exocytosis when synaptosomes were subsequently depolarized.
The complex, multistep cascade of events accounting for the dynamic long-lasting functional
modification in synaptosomes remains so far unexplored. Nonetheless, the results were particularly
relevant as they first suggested that:
(i) synaptosomes are dynamic structures that can develop functionally relevant adaptations when
exposed acutely “in vitro” to external chemical stimuli;
(ii) the acute chemical-induced synaptosomal adaptations persist well beyond the physical occupancy
of the selected receptor binding site(s), and possibly rely on a drug-induced cascade of events
that primes persistently the functions of the isolated nerve endings.
(iii) the timing of the onset of the synaptosomal adaptation (about 20 min) tends to exclude that genetic
and/or epigenetic modifications can underlie these adaptations, provided that synaptosomes
possess the repertoire permitting such a kind of events.
About a decade later, a comparable form of “in vitro” chemically-induced long-lasting “presynaptic
memory” in nerve endings was described. In this case, functional adaptations were elicited by exposing
in superfusion synaptosomes from the nucleus accumbens to nicotine and/or nicotinic agonists before
the application of a mild depolarization elicited by the transient activation of ionotropic glutamate
receptors. Synaptosomes were pretreated with standard Kreb’s solution containing nicotine itself or
nicotine agonists (at concentrations unable to modify on their own transmitter release) and thereafter
challenged with NMDA in the presence of glycine to activate presynaptic release-regulating NMDA
receptors and/or AMPA to activate non-NMDA receptors. Again, drug-induced long-lasting adaptation
emerged as changes in the efficacy of transmitter exocytosis, measured in this case as release of dopamine
elicited by the presynaptic release-regulating ionotropic glutamate receptors [32,54,55] (Table 1).
The study originated from data in literature showing that the dopaminergic nerve endings
from the nucleus accumbens possess nicotinic receptors that coexist and cooperate with presynaptic
release-regulating NMDA and AMPA receptors [38,56–58]. When concomitantly activated, nicotinic
receptors were synergic to both the AMPA and the NMDA-mediated releasing activity, reinforcing
it [16,56]. The impact of nicotine on ionotropic glutamate receptors, however, drastically changed
when synaptosomes were pre-exposed to the cholinergic agonist. Mario Marchi and his colleagues [32]
described that the transient activation of nicotinic receptors primes the subunit composition of both
the ionotropic glutamate receptors and, consequently, their efficiency in controlling dopamine release.
In both cases, pre-exposure of synaptosomes caused a rapid internalization of selected receptor
subunits (the GluN2B subunit for the NMDA receptors and the GluA2 subunit for the AMPA receptors),
then modifying the number and/or the Ca2+ permeability of the ionic channels associated to both the
presynaptic release regulating ionotropic glutamate receptors, hampering dopamine exocytosis.
It is known that AMPA and NMDA receptors undergo rapid constitutive trafficking (which occurs
within few minutes; see [5] and references therein) that would account for the functional changes
in nicotine-treated particles. This event, however, would quickly recover because of the activation
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of constitutive compensatory mechanism(s) of insertion of new receptors to re-equilibrate their
physiological expression in synaptosomal plasmamembranes. The data from the release experiments
showing that nicotine-induced changes to the insertion of AMPA and NMDA receptor subunits in
synaptosomal plasmamembranes persist during time would suggest that the kinetic of endocytosis of
the glutamate receptor subunits is accelerated in treated synaptosomes, but, concomitantly, that the
constitutive mechanisms of restoration of the glutamatergic receptor subunits insertion is slowed down.
More recently, another form of “in vitro” drug-induced, long-lasting presynaptic adaptation
was described to occur in rat hippocampal synaptosomes. In this case, the presynaptic adaptation
was induced by exposing synaptosomes to low nanomolar concentration of CXCL12, a chemokine
that is a marker of central inflammation [59]. CXCL12 is the natural ligand of the CXCR4 receptors,
a chemokine receptor that coexists and functionally cross-talks with presynaptic NMDA receptors in
both glutamatergic and noradrenergic rat hippocampal nerve endings [60]. CXCL12 acting at CXCR4
receptors cannot release glutamate and noradrenaline on its own but sinergically potentiates the
NMDA-evoked release of both transmitters when the CXCR4 and NMDA receptors are concomitantly
exposed to the respective agonists. CXCL12-induced positive modulation, however, turns to inhibition
when synaptosomes are exposed transiently (20 min) to the chemokine before the application of the
depolarizing stimulus (the NMDA/glycine challenge). In this case, the loss of release efficiency relied
on changes in the phosphorylation of the GluN1 subunit in Serine 896 [61] (Table 1).
Table 1. In vitro” persistent “presynaptic adaptation” in synaptosomes.













25 mM KCl for
30 s ⇓ [11]
Rat Nucleus
Accumbens [
3H]dopamine Nicotine (30 µM) 100 µM NMDA ⇓ [32,55]
Rat Nucleus
Accumbens [
3H]dopamine Nicotine (30 µM) 100 µM AMPA ⇓ [32,54]
Rat
hippocampus [
3H] aspartate CXCL12 (3 nM)
30 µM NMDA/





CXCL12 (3 nM) 100 µM NMDA/3 nM CXCL12 ⇓ [60,61]
The table summarizes the results from “in vitro” experiments, showing a persistent adaptation of synaptosomes
elicited by exposing them transiently to enzyme modulators as well as to agonists of presynaptic receptors.
Synaptosomes were superfused with a Kreb’s ringer containing the drug indicated in the third column and then
exposed to a mild depolarizing stimulus (see the fourth column) to monitor the efficiency of glutamate exocytosis.
The results clearly unveiled a significant reduction of transmitter exocytosis in those synaptosomes that were
pre-exposed to the drugs when compared to control. ⇓= reduced.
To briefly resume, the results described in this paragraph provide evidence that synaptosomes are
plastic entities that can undergo persistent functional and structural “in vitro” modifications when
exposed to chemicals, suggesting that they can memorize ligand-induced signaling, then modifying
their functional outcomes. In some cases, the mechanisms at the basis of these plastic adaptations
have been in part elucidated and suggest the involvement of altered receptor in–out trafficking in
synaptosomal plasmamembranes and/or changes in the level of phosphorylation of the receptor
subunits. Further investigations are, however, required to better address the cascade of events
accounting for the duration of these adaptations in synaptosomes.
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8. Acute “In Vivo” Drug Administration Elicits Persistent Presynaptic Adaptation in
Synaptosomes
In 2007, a study was carried out to evaluate whether and to what extent “in vivo” administration
of classic antidepressants (i.e., reboxetine and fluoxetine) could affect the exocytosis of noradrenaline
and serotonin from rat hippocampal synaptosomes [8].
An interesting observation of the study was that the ”in vivo” acute administration of reboxetine
almost halved the “ex-vivo, in vitro” exocytosis of both transmitters in hippocampal synaptosomes,
while acute ”in vivo” fluoxetine administration significantly reduced the “ex-vivo, in vitro” exocytosis
of serotonin, leaving unmodified the “ex-vivo, in vitro” KCl-evoked release of noradrenaline. In an
attempt to find a rationale, it was proposed that the “in vivo” antidepressant-induced modification
of the “ex vivo, in vitro” amine exocytosis could represent the consequence of the transient “in vivo”
blockade of the noradrenergic and the serotonergic transporters that in turn could have primed both the
noradrenergic and the serotonergic terminals, affecting their efficiency in releasing the two transmitters.
It was speculated that both the noradrenaline and serotonin reuptake inhibitors could have augmented
the extracellular concentration of the two amines in the synaptic cleft, indirectly favoring the activation
of presynaptic auto- and heteroreceptors (Figure 1).
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Figure 1. The ca toon d s ribes the mechanisms proposed to trigge the “ex-vivo, in vitro” modifications
of noradrenaline and serotonin exocytosis (blue arrow) in hippocampal synaptosomes isolated from
animals acutely treated with reboxetine (middle) or fluoxetine (bottom) when compared to control condition
(untreated animal , top). Noradrenergic terminals poss ss α2 autorec ptors, while er tonergic receptors
possess both 5HT1B autoreceptors and α2 heteroreceptors. It is proposed that the “in vivo” activation
of both the α2 autoreceptors and the α2 heteroreceptors that would follow the acute administration of
reboxetine might account for the reduced exocytosis of both noradrenaline and serotonin, while, based
on notion that noradrenergic terminals do not possess serotonergic release-regulating heteroreceptors
(left side of the Figure), serotonin-induced activation of serotonergic receptors in fluoxetine-treated
animals only can occur at serotonergic terminals. The functional adaptations elicited by the “in vivo”
activation of the presynaptic release-regulating receptors are retained by isolated synaptosomes and
emerge subsequently in “in vitro” studies as changes in release efficiency (right side of the panel).
Reboxetine and fluoxetine block the NA transporter (NET) and the 5HT transporter (SERT, circular arrow),
increasing NA and 5HT bioavailability in the synaptic cleft. Synaptosomes were labelled with radioactive
tracers and superfused with superfusion medium (black arrow). Synaptosomes were transiently (90 s)
exposed to a depolarizing stimulus (the red line indicating the change in membrane potential) that causes
vesicular exocytosis (red arrow) of transmitters (black dots).
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As to this possibility, it is worth reminding that noradrenergic nerve terminals are endowed
with inhibitory α2 autoreceptors [62–65], while serotonergic terminals possess inhibitory 5-HT1B
autoreceptors [66,67]. Interestingly, inhibitory α2 adrenergic heteroreceptors also exist in serotonergic
terminals [68], while data supporting the presence of 5-HT heteroreceptors regulating the release
of noradrenaline in noradrenergic terminals are lacking [69]. Although the possibility exists that
“in vivo” fluoxetine and reboxetine could also target other membrane targets [70], the distribution of
the auto- and the heteroreceptors in noradrenergic and serotonergic appeared well consistent with
the functional adaptations observed in hippocampal synaptosomes from rat administered acutely
with the two antidepressants. Actually, the “in vivo” activation of both the α2 autoreceptors and the
α2 heteroreceptors that would follow the acute administration of reboxetine could account for the
reduced exocytosis of both noradrenaline and serotonin, while, based on the data so far available in the
literature, serotonin-induced activation of serotonergic receptors only occurs at serotonergic terminals,
since noradrenergic terminals do not possess serotonin release-regulating heteroreceptors.
In an attempt to confirm the hypothesis that the acute “in vivo” activation of presynaptic α2
receptors can cause “ex vivo, in vitro” adaptation in synaptosomes isolated from the hippocampus,
animals administered acutely with desipramine were concomitantly and acutely injected with yohimbine
(a selective α2 receptors antagonist). In accordance with expectations, the “in vivo” administration of
the antidepressant primed noradrenergic nerve endings and adaptation emerged in “ex vivo, in vitro”
release experiments as a drastic reduction of the K+-evoked release of NA when compared to control [71].
The “ex vivo, in vitro” adaptation of NA exocytosis, however, was no more detectable in hippocampal
synaptosomes from animals administered with desipramine plus yohimbine. [71] (Table 2).
To conclude, the acute administration of a noradrenaline uptake blocker causes the rapid onset
of persistent adaptive changes in hippocampal noradrenergic synaptic boutons that are retained by
ex-vivo nerve endings, after isolation from hippocampus homogenates and washing with drug-free
solutions and that emerged in “ex vivo, in vitro” study as reduced exocytosis efficiency. To note,
the onset of the functional long-lasting presynaptic adaptation strictly relies on the activation of the
orthosteric binding site of the α2 receptors, as suggested by the efficacy of the co-administration of
yohimbine in preventing the presynaptic event. Interestingly, the “in vivo” chronic administration of a
noradrenaline transporter blocker did not cause significant changes in the efficiency of noradrenaline
exocytosis in “ex vivo, in vitro” experiments, possibly because of the downregulation of theα2 receptors
due to the prolonged increased availability of the extracellular endogenous amine elicited by the
drugs [8]. Nonetheless, the reboxetine-induced “ex vivo, in vitro” induction of serotonin exocytosis
efficiency was still detectable after chronic administration of the carrier blocker, consistent with the
view that heteroreceptors do not desensitize following prolonged exposure of the natural ligand.
The mechanisms involved in the downregulation of the presynaptic release-regulating
noradrenergic and serotonergic receptors are so far unknown, but the possibility exists that in
this case, epigenetic and/or genetic events could participate to the changes in release efficiency. Further
studies are required to address these aspects.
9. Acute “In Vivo” Drug-Induced Adaptation at Glutamatergic Nerve Endings: Implications in
Pathological Conditions
Glutamatergic nerve endings possess both ionotropic and metabotropic presynaptic
release-regulating receptors, whose activation affects differently glutamate exocytosis. In general,
ionotropic autoreceptors (both NMDA and non-NMDA) elicit the release of glutamate in the absence
of concomitant depolarizing stimuli. Differently, metabotropic glutamate receptors (mGlu) finely
tune this event when concomitantly added to a depolarizing stimulus. In particular, mGlu receptors
belonging to group I permit and reinforce glutamate overflow, while the mGlu receptors belonging to
the II (namely, mGlu2/3 receptors) and III group (in particular, mGlu4 and mGlu7 receptor subtypes)
inhibit it [39,43].
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The hypothesis that the “in vivo” acute activation of presynaptic autoreceptors could prime nerve
endings causing persistent modification at the presynaptic component of chemical synapsis was
confirmed also when studying the role of mGlu2/3 autoreceptors on glutamate exocytosis in both
cortical and spinal cord nerve endings of mice. The mGlu2/3 autoreceptors controlling the glutamate
exocytosis from the two synaptosomal subpopulations differ in term of affinity and efficacy of selective
mGlu2/3 agonists/antagonists, compatible with the conclusion that they represent different mGu2/3
receptor subtypes [72].
In line with the proposed onset of synaptic adaptation due to the acute administration of
agonists, the acute “in vivo” injection of LY379268, a broad spectrum mGlu2/3 agonist, caused persistent
modifications to both the cortical and the spinal cord glutamatergic nerve endings that were reminiscent
of the presynaptic inhibitory control exerted by mGlu2/3 autoreceptors in these terminals. Actually,
“in vitro” glutamate exocytosis evoked by a mild depolarizing stimulus from the synaptosomes isolated
from both the CNS regions (i.e., the cortex and the spinal cord) of the “in vivo” treated animals was
significantly reduced when compared to that from control untreated animals [71–75].
Again, the hypothesis that synaptosomes could have “memorized” the consequences due to
the “in vivo” acute activation of the presynaptic autoreceptor agonist well supported the “ex vivo,
in vitro” observations.
Multiple sclerosis (MS) is an autoimmune inflammatory disease with unknown etiology. Overt
demyelination and inflammation develop in selected regions of the central nervous system (CNS).
Comparable histological hallmarks are also detected in the CNS of mice suffering from experimental
autoimmune encephalomyelitis (EAE). In addition to inflammation and demyelination, a diffuse loss
of synaptic contact, axonal pruning, and astrocytosis was also reported to occur in the CNS of patients
suffering from MS and in EAE mice. These observations led to proposing the term “synaptopathy” to
describe the demyelinating pathology [76]. As to the synaptic defects, several observations in the last
decade supported the onset of altered glutamate release efficiency from synaptosomes isolated from
selected CNS regions of EAE mice at different stages of disease [77].
Table 2. “ex vivo, in vitro” persistent “presynaptic adaptation” in synaptosomes.
In Vivo Treatment “Ex Vivo, In Vitro” Synaptosomes Adaptations
Drug Treatment SynaptosomalPreparation Transmitter
Stimulus
Applied Outcome Ref.
reboxetine 10 mg/Kg, os rathippocampus [
3H]noradrenaline 12 mM KCl ⇓ [8]
reboxetine 10 mg/Kg, os rathippocampus [
3H]serotonin 12 mM KCl ⇓ [8]




0.5 mg/Kg i.p. mice cortex [
3H]noradrenaline 12 mM KCl
No
effect [71]
fluoxetine 10 mg/Kg, i.p. Rathippocampus [
3H]serotonin 12 mM KCl ⇓ [8]
fluoxetine 10 mg/Kg, i.p. Rathippocampus [
3H]noradrenaline 12 mM KCl
No
effect [8]
LY379268 1 mg/Kg, i.p. Mouse spinalcord [
3H]D-aspartate 15 mM KCl ⇓ [76]
The table summarizes the results from “ex vivo, in vitro” experiments showing a persistent adaptation in
synaptosomes elicited by “in vivo” acute administration of drugs that modulate the functions of presynaptic
release-regulating receptors. It is proposed that the acute administration of receptor ligands or carrier modulators
elicit functional remodeling of the synaptic proteasome. The persistent “in vivo” adaptive changes in synaptic
boutons are retained by nerve endings, after isolation from the hippocampus and washing with drug-free solutions,
and emerge in “ex vivo, in vitro” study as reduced exocytosis efficiency. ⇓= reduced.
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To investigate whether the “in vivo” mGlu2/3-induced chemical presynaptic adaptation also
occurs in pathological conditions typified by altered glutamatergic innervation, the same experimental
paradigm used above in healthy mice was applied to animals suffering from EAE [72]. The data
available in the literature demonstrated that the efficiency of glutamate exocytosis from cortical
nerve endings is drastically reduced in EAE mice when compared to controls, possibly because of
the significant reduction of the intraterminal cyclic Adenylyl cyclase-mediated pathway. Differently,
glutamate exocytosis from the spinal cord synaptosomes from EAE mice significantly increases when
compared to control.
The acute intraperitoneal injection of LY379268 in EAE mice at the acute stage of disease failed to
affect the glutamate exocytosis from cortical nerve endings. Since the mGlu2/3 autoreceptors negatively
couple adenylyl cyclase-dependent pathways, it was proposed that the reduced efficiency of this
enzyme in the glutamatergic cortex of EAE mice at that stage of disease could mainly account for
the loss of function of the “in vivo” mGlu2/3 agonist to prime cortical glutamatergic nerve endings.
Differently, “in vivo” acute LY379268 efficiently reduced the “in vitro” glutamate exocytosis from
superfused spinal cord synaptosomes [72]. This observation is particularly relevant from a therapeutic
point of view, since clinical observations suggest that MS patients suffer from a reduction in the
production of N-acetyl aspartyl glutamate (NAAG), an endogenous dipeptide that acts as a full agonist
at mGlu2/3 autoreceptors in the spinal cord. Accordingly, either mGlu2/3 receptor agonist as well as
inhibitors of the glutamate carboxypeptidase II (GCPII), i.e., the enzyme catalyzing the cleavage of
endogenous NAAG to N-acetyl aspartate and glutamate, were recently proposed to be beneficial for
the course of the disease. The data described above could in part give the rationale to the use of NAAG
modulators for the cure of MS.
10. Concluding Remarks
This review aimed at discussing the data available that support the notion that presynaptic nerve
endings can learn and memorize acute chemical stimulations.
The functional and structural adaptations at the basis of this form of “chemically-induced
presynaptic memory” develop either “in vitro”, after the acute exposure of synaptosomes to the
triggering chemical, or “in vivo”, by acutely administering animals with the drug.
In both cases, adaptations were retained beyond the removal of the triggering agents and emerged
subsequently as changes in release efficiency and/or receptor-mediated events in “in vitro” experiments.
The discovery of this chemically induced long-lasting memory expands our knowledge of the
functional role of the presynaptic component of chemical synapses, also paving the road to new
investigations concerning the impact of acute drug administration on neurotransmission. The finding
that nerve endings can memorize chemical stimuli and that this presynaptic adaptation can emerge in
“in vitro” studies open the possibility to evaluate the impact of the drugs in either physiological or
pathological conditions, allowing also to identify drug-induced effects that do not necessarily imply a
direct control of transmitter exocytosis. As to this regard, it is worth reminding that in recent years,
attention was given to the mechanisms of “metamodulation”. The term of metamodulation refers to
the possibility that different neurotransmitters can cooperate to modulate transmitter exocytosis in
the CNS. Actually, although chemicals are often analyzed individually for their effects, the possibility
that they can prime nerve endings and indirectly modify the release efficiency at nerve terminals
as well as the expression and functions of the presynaptic receptors in plasmamembranes increases
hugely the complexity of the scenario and must be taken into account when considering the impact of
the occasional co-administration of therapeutics. Similarly, as environmental stimulation can control
central transmission, rearing animals in enriched conditions as well as their stressful handling could
cause acute central adaptation that might account for experimental variability.
Based on the data described in this review, the “chemically-induced presynaptic memory” elicited
by acute exposure to drugs offers, on one hand, the possibility to investigate the cascades of events
tuning synaptic transmission, but, on the other hand, it also unveils unexpected events leading to
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side effects due to anomalous adaptation of synaptic terminals and/or presynaptic release-regulating
receptors that must be taken into consideration when evaluating the pharmacological profile of the
receptors targeted at chemical synapsis.
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